Crockett Elementary student's quick thinking saves classmate from allergic reaction
Not only does Crockett Elementary try to instill that in their kids, but it's also how Alyssandra Oviedo was raised.
'What do you like learning about?' I asked Alyssandra.
'I kinda like math!' Alyssandra said.
Meet six-year-old Alyssandra Oviedo.
'What's your favorite part about recess?' I asked.
'Playground!' Alyssandra exclaimed.
She's a first-grader at Crockett in Mr. Maxwell's classroom.
On Monday, March 21, was just another day for Alyssandra. Mr. Maxwell, who is teaching at the front of the class, lights off when she notices something wrong with her classmate.
'I was basically just doing something on my Chromebook when I saw her face was pink, and her cheek was red, but not that much. The other cheek was a little redder,' Alyssandra said.
Leading Alyssandra to take action.
'I tell her to go tell Mr. Maxwell,' Alyssandra said.
'We turned the lights on, and sure enough, she was beginning to have an allergic reaction to some medication she had taken just minutes before,' Robert Maxwell said. 'I was writing the nurse's note, and I could see it spreading. As I was talking to her about it, which signs did she feel she eventually started to feel the itching from it. I could see it going across her chest.'
The quick action from Alyssandra leads to quick treatment for the classmate.
Avoiding more pain from her allergic reaction. Her heroics did not go unnoticed.
Teacher Robert Maxwell commended Alessandra's awareness. But also the goodness in her heart to speak up.
'This is a lesson she's already learned and passed,' Maxwell said. 'When you look at it being six years old, I mean, how many people in their 30s and 40s and even me older than that, sometimes you've noticed something. You wonder, 'should I say something' as you're already walking away, and then afterwards, you hear about it and go, 'oh, well, yeah, I noticed that.''
Alyssandra received a medal from the Thomas Fowler American Legion Post 169 and a positive office referral.
'What was your reaction whenever you saw that you were actually getting an award?' I asked.
'Excited!' Alyssandra said.
Though Alyssandra doesn't feel like a hero.
'How does that make you feel knowing you helped your friend?' I asked.
'Like a good friend,' Alyssandra said.
She's happy to have her deskmate back in class.
Alessandra is set to be honored by the WFISD school board on Monday evening.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
02-08-2025
- Yahoo
Citi Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-07-2025
- Business Wire
Longhorn Vaccines and Diagnostics Partners with Promega to Combine Complementary Offerings for Enhanced Sample Collection, Transport and Analysis
BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)-- Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced a strategic co-marketing agreement with Promega Corporation to deliver integrated molecular testing solutions designed to enhance safety, efficiency and flexibility across a wide range of diagnostic settings. This collaboration brings together Longhorn's validated PrimeStore® Molecular Transport Medium (MTM) and Promega's Maxwell® automated nucleic acid extraction platform, delivering a powerful, end-to-end workflow to support an all-in-one solution for safer and enhanced virus sample collection, transportation and analysis. Longhorn's PrimeStore® MTM is an inactivating molecular transport medium for both RNA and DNA. The device delivers nucleic acid samples in a time-efficient manner with Promega's Maxwell® instruments and reagent kits, designed for the automated extraction of viral total nucleic acid from a range of sample types. 'The accuracy of molecular diagnostics, PCR and sequencing, starts with high quality nucleic acid,' said Longhorn Vaccine and Diagnostics President Jeff Fischer. 'Promega has proven that PrimeStore® MTM does just that with validation testing on their Maxwell® platform. Samples are safe to handle outside of containment, speeding up the testing time and therefore speeding up the accurate treatment of patients. The Maxwell® platform and nucleic acid extraction kits are now being added to our Instructions for Use.' 'Together, these technologies streamline the workflow from sample collection to high-quality nucleic acid purification without compromising on safety or performance,' said Promega Director of Applied Markets Julie Yang. Longhorn and Promega will showcase their combined technologies at the upcoming Association for Diagnostics & Laboratory Medicine conference (ADLM 2025) in Chicago from July 29-31, 2025. Visit booth #3757 to learn more about PrimeStore® MTM and booth #3655 to learn more about the Maxwell® instruments and nucleic acid purification kits. A joint poster showcasing how these technologies work together was presented at the May 2025 Association of Public Health Laboratories annual conference in Portland, Oregon, titled ' Validation of a Novel Sample Collection-to-Detection Workflow Using PrimeStore® MTM, Pathogen Total Nucleic Acid Kit, and PrimeMix® MTB.' A second joint poster was presented at the June 2025 International Symposium of the World Association of Veterinary Laboratory Diagnosticians conference in Calgary, Alberta, titled ' Novel Biosafe and Scalable Detection of Influenza A (H5N1, H3N2, H1N1) for Veterinary and One Health Applications.' For more information about Longhorn, visit About Longhorn Vaccines and Diagnostics Longhorn Vaccines and Diagnostics is a closely held One Health company based in Maryland that is developing broad coverage vaccines and diagnostic tools for worldwide public health concerns such as anti-microbial resistance, sepsis and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing broad coverage vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn products play a significant role to surveil, diagnose, prevent and treat the next infectious disease. Longhorn's core diagnostic product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. About Promega Corporation Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.
Indianapolis Star
07-07-2025
- Indianapolis Star
Hundreds donated breast tissue during Indy Super Bowl. Now you can help during All-Star Weekend
In 2012, nearly 700 women donated healthy breast tissue during the NFL Super Bowl in Indianapolis, which became the world's largest single-day donation event of its kind. Now, as the city prepares to host the WNBA All-Star Weekend, that momentum returns with the All-Star Cure. On July 12 and 13, one weekend before the All-Star Game, the Komen Tissue Bank at the IU Simon Comprehensive Cancer Center will host its second-largest event ever, aiming to collect breast tissue samples from 500 women at the IU Simon Care Center. Organizers are counting on the energy surrounding women's basketball, and the star power of Indiana Fever's Caitlin Clark, to draw broader visibility and participation. "This is a real opportunity to encourage women under the age of 40 to participate in these studies to ensure that we're advancing research and treatments representative of all women," said Portia-Bailey Bernard, a WNBA host committee member. Bailey-Bernard, who has donated to the tissue bank, said she "would do it over and over and over again." The news of breast cancer diagnoses in her own circle, she said, felt "debilitating," and she sees her donations as an empowering step forward. As a former athlete, Bailey-Bernard said that she's never seen energy around women's sports at this level and believes the moment presents a powerful opportunity to drive positive attention to women's health. She added that getting involved with the cause gave her a chance to create generational impact. Bernard and her four-year-old daughter, Maxwell, are regulars at Indiana Fever games. By bringing Maxwell to the All-Star Cure event, Bernard hopes to show her just how powerful it can be when a community rallies together. "Everything in the world is so polarizing right now," she said. "With All-Star weekend, I want (Maxwell) to see what we can do as a community when we put aside those differences to showcase our team and our city." The All-Star Cure builds on the legacy of the 2012 Super Cure by addressing gaps in research, particularly the need for more racially diverse and younger donors. Organizers like Kathi Ridley-Merriweather are calling on Black, Latina, and Asian women to help close the gap. "There's been all kinds of amazing discoveries made in breast cancer," Merriweather said. "Unfortunately, those discoveries have been made by studying primarily white women over 50, and they do not have the same results in other populations." According to the Breast Cancer Research Foundation, Black women are 40% more likely to die from breast cancer than white women. Among younger patients, the disparity is even greater with Black women facing nearly double the mortality rate. As the outreach lead, Merriweather said her role is to build trust in communities of color that have long been left out or harmed by the medical system. "I am upholding and validating feelings of fear and hesitation," she said. "Oftentimes, these population members are afraid to ask the questions that they really want to know because they have not been taken seriously. I'm out there to take them seriously." Other organizers like Jill Henry said for most people, joining a clinical trial only happens after a diagnosis. This event, she said, flips that, inviting healthy women to contribute to preventative research. Each donor undergoes a short health screening and a minor outpatient procedure to collect a small amount of breast tissue under local anesthesia. The process takes about an hour. Scientists use these healthy tissue samples as a baseline to detect early cellular changes. "We send these samples to researchers around the world from Australia to Norway and labs here in the U.S.," Henry said. "I'm certainly not the one doing the research, but I support the research so that it can move forward to help my daughter and hopefully minimize the breast cancer impact to future generations." All-Star Cure takes place in four shifts over July 12 and 13. Interested participants can learn more and register at Organizers are aiming for a diverse group of women over 18 who are in general good health and not currently pregnant or nursing. "It's empowering to know that a little bit of breast tissue and 60 minutes of my day went to long-term lasting impact," Bernard said. "To be a part of something that's truly bigger than yourself."
